US78667J1088 - SAGE - A117WF (XNMS)
SAGE THERAPEUTICSCS INC Aktie
7,90 USD
Aktuelle Kurse von SAGE THERAPEUTICSCS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
SAGE
|
USD
|
19.09.2024 22:00
|
7,90 USD
| 7,59 USD | 4,08 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 0,89 % | -8,67 % | -26,51 % | -59,02 % | -61,37 % | -95,17 % |
Firmenprofil zu SAGE THERAPEUTICSCS INC Aktie
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Investierte Fonds
Folgende Fonds haben in SAGE THERAPEUTICSCS INC investiert:
Fonds | Vol. in Mio 93,46 | Anteil (%) 0,22 % |
Unternehmensdaten zur SAGE THERAPEUTICSCS INC Aktie
Name SAGE THERAPEUTICSCS INC
Firma Sage Therapeutics, Inc.
Symbol SAGE
Website https://www.sagerx.com
Heimatbörse
NASDAQ/NMS (GLOBAL MARKET)
WKN A117WF
ISIN US78667J1088
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Barry E. Greene
Marktkapitalisierung 458 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,5 T
Adresse 215 First Street, 02142 Cambridge
IPO Datum 2014-07-18
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | SG7.F |
NASDAQ | SAGE |
Weitere Aktien
Investoren die SAGE THERAPEUTICSCS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024